Full Press Release Details
Arnika K. Wagner, Ph.D. Assistant Professor, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm Former Dean of Research, Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm Hans - Gustaf Ljunggren, M.D., Ph.D. 28 2022 Coeptis Therapeutics, Inc.
AGREEMENT TERMS If consummated, Coeptis would pay $6,000,000 (funded with a debt facility) and revenue - based milestone payments to be defined in the definitive agreement in exchange for a defined set of purchased assets that include rights to any product containing entolimod as an active ingredient and all other related TLR5 agonists DEVELOP & ADVANCE STRATEGIC AGREEMENT Coeptis Strategic Agreement - TLR5 Agonist Platform 26 2022 Coeptis Therapeutics, Inc.
Among the initial cancer indications under development are pre - clinical programs targeting breast cancer and ovarian cancer CAR - T cell therapy market size & share expected to reach $20.56 billion by 2029 from $1.96 billion in 2021, at a compound annual growth rate (CAGR) of 31.6% during forecast period 2022 to 2029. 1 1 Source: Polaris Market Research 24 2022 Coeptis Therapeutics, Inc.
Exclusive option agreement involves the intellectual property rights to three technologies : mSA2 affinity - enhanced biotin - binding CAR Universal self - labeling SynNotch and CARs for programable antigen - targeting Conditional control of universal CAR - T cells through stimulus - reactive adaptors PARTNERSHIP STATUS Coeptis has until October 29, 2022, to exercise the option.
Being developed to pre - determine which cancer patients are most likely to benefit from targeted anti - CD38 mAb therapies , either as monotherapy or in combination with CD38 - GEAR - NK. Potential to develop as platform technology beyond CD38 to identify patients likely to benefit for a broad range of mAb therapies across multiple indications . CD38 - Diagnostic - Product Overview 1 2 3 19 2022 Coeptis Therapeutics, Inc.
CD38 - GEAR - NK are modified, NK cells that can avoid being ablated by therapies designed to target the CD38 antigen, thus enabling the combination of passive immunity with innate active immunity to more efficiently target and eradicate CD38+ malignancies. CURRENT ANTI - CD38 PATHWAY PATHWAY WITH GEAR - NK (CD38) CELL THERAPY 17 2022 Coeptis Therapeutics, Inc.
A NOVEL COMBINATORIAL APPROACH Modified NK cells that are co - administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre - clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible. GEAR - NK (CD38) STRATEGY Animations herein are provided as visual aids to help articulate hypothesized proof - of - concept in a general manner and do not depict precise scientific mechanisms - of - action. 16 2022 Coeptis Therapeutics, Inc.
PARTNERSHIP STATUS Coeptis currently has a 50% (which could scale down to 25%) revenue stream interest and co - development rights for CD38 - GEAR - NK and a 50% revenue stream interest related to CD38 - Diagnostic from VyGen - Bio. Coeptis is entitled to receive future revenue from both products. DEVELOP & COMMERCIALIZE EXCLUSIVE OPTION AGREEMENT Coeptis Collaboration - VyGen - Bio 15 2022 Coeptis Therapeutics, Inc.
Coeptis will assist VyGen - Bio in its efforts to develop and commercialize: CD38 - GEAR - NK , is a pre - clinical in vitro proof of concept product designed to protect CD38+ NK cells from destruction by anti - CD38 mAbs. CD38 - Diagnostic , a discovery - stage product designed to analyze if cancer patients might be appropriate candidates for anti - CD38 mAb therapy.
Business Combination value agreed to prior to TRL5 agonist and Pitt agreements, suggesting near - term and longer - range upside potential. Q2 21 Q3 '21 5/18/21 Coeptis Enters into Exclusive Option Agreements w/ VyGen - Bio 8/19/21 Coeptis Therapeutics Partners with VyGen - Bio, Inc. to Co - develop Two Assets Designed to Improve the Treatment of CD38 - Related Cancers 4/19/22 Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp.
At the close of the transaction, Bull Horn will be rebranded with "Coeptis" in its name and expects to be listed on Nasdaq under the ticker symbol "COEP." Bull Horn to re - domesticate to Delaware. GO - FORWARD PLAN Merger provides Coeptis access to capital needed to advance product portfolio highlighted by CD38 - GEAR - NK and CD38 - Diagnostic; license/acquire Pitt and TLR5 agonist assets.
CAR - T platform early - indications offer potential to target hematologic and solid tumors, including breast and ovarian cancer. Right to acquire toll - like receptor 5 (TLR5) agonist platform, including entolimod . Entolimod is a clinical - stage product currently being developed as a treatment for acute radiation syndrome. Corporate Highlights 12 2022 Coeptis Therapeutics, Inc.
VyGen - Bio's GEAR - NK enables development of modified NK cell - based therapeutics optimized to be co - administered with targeted antibodies. CD38 - GEAR - NK are modified NK cells that can avoid being ablated by therapies designed to target the CD38 antigen. Exclusive option agreement with University of Pittsburgh provides access to three potentially groundbreaking CAR - T technologies.
Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Ma ny actual events and circumstances are beyond the control of Bull Horn and Coeptis. Some important factors that could cause actual res ult s to differ materially from those in any forward - looking statements could include changes in domestic and foreign business, market, financia l, political and legal conditions.
The forward - looking statements include, but are n ot limited to, statements concerning the expected terms and timing of the Business Combination and any financing undertaken in connectio n w ith the Business Combination. The forward - looking statements made in this Presentation are based on Coeptis' current assumptions and judgments regarding futur e events and results.
Forward - looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticip ate," "intend," "expect," "should," "would," "plan," "future," "outlook," and similar expressions that predict or indicate future events or t ren ds. All statements that are not statements of historical matters are forward - looking statements.
Forward - looking statements are neither historical facts nor ass urances of future performance. Because forward - looking statements relate to the future, they are inherently subject to significant known an d unknown risks, uncertainties and other factors that are difficult to predict and are beyond the control of both Bull Horn and Coeptis . The actual results, level of activity, performance or achievements of Bull Horn or Coeptis may be materially different from any future results, l eve ls of activity, performance or achievements expressed or implied by these forwards - looking statements.
The risks presented in such filings will b e c onsistent with those that would be required for a public company in its SEC filings, including with respect to the business and securit ies of Coeptis and Bull Horn and the proposed Business Combination, and may differ significantly from, and be more extensive than, the follo win g risks presented below. - The consummation of the Business Combination is subject to a number of conditions, and if any of those conditions are not sat isfied or waived, Business Combination may not be completed; Risk Factors 7 2022 Coeptis Therapeutics, Inc.
You should review this presentation and perform your own due diligence and cons ult with your own financial and legal advisors prior to making any decision in respect of Bull Horn, Coeptis or the Company. Risks relating to the business of Coeptis and Bull Horn will be disclosed in future documents filed or furnished by Coeptis and/or Bull Horn with the SEC, i ncl uding the documents filed or furnished in connection with the proposed Business Combination.
If Coeptis canno t a ddress any of the following risks and uncertainties effectively, or any other risks and difficulties that may arise in the future, its busi nes s. financial condition and results of operations could be materially and adversely affected. The risks described below are not the only risks that C oep tis or Bull Horn faces. Additional risks that are currently not known about or that are currently believed to be immaterial may also impa ir its business, financial condition or results of operations.
The list bel ow has been prepared solely for purposes of this presentation and not for any other purpose. The list below is qualified in its entirety by disclosures contained in documents previously or hereafter filed or furnished by Bull Horn or Coeptis with the SEC, and you should carefu lly consider these risks and uncertainties, together with the financial statements and related notes filed with the SEC.
This Presentation is not a substitute for the proxy statement/prospectus or for any other document that Bull Horn or Coeptis may file with the SEC in connection with the Business Combination. INVESTORS AND SECURITYHOLDERS ARE ADVISED TO READ THE DOCUMENTS FILED WITH THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
Date of Information: This Presentation speaks only as of the date hereof. Neither Bull Horn nor Coeptis intend to update or otherwise revise this Presentation following its distribution, except the extent required by law. Neither Bull Horn nor Coeptis makes any rep res entation or warranty, express or implied, as to the accuracy of completeness of any of the information contained in this Presentation.
To the fullest e xte nt permitted by law, in no circumstances will Bull Horn, Coeptis or any of their respective subsidiaries, shareholders, affiliates, represent ati ves, control persons, partners, members, managers, directors, officers, employees, advisers or agents be responsible or liable for any dir ect , indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents, its omissions, reliance on the inf ormation contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith.
The general explan ati ons included in this Presentation are not intended to, and cannot, address your specific investment objectives, financial situati ons or financial needs. You should consult with you own legal counsel and tax and financial advisors as to legal and related matters concerni ng the matters described herein, and, by accepting this Presentation, you confirm that you are not relying solely upon the information conta ine d herein to make any investment decision. 5 2022 Coeptis Therapeutics, Inc.
The information contained in the Presentation does not purport to be all - inclusive or to contain all information that may be req uired to make a full analysis of an investment in Bull Horn, Coeptis or the Business Combination, and you should conduct your own inde pen dent evaluation and due diligence with respect to Bull Horn, Coeptis and the terms of the Business Combination.
Interested persons are advised to read the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Bull Horn, Coe pti s and the Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials relating to the pr oposed Business Combination will be mailed to shareholders of Bull Horn and Coeptis as of a record date to be established for voting on the proposed Business Combination.
Additional Information and Proxy Statement: In connection with the proposed Business Combination, Bull Horn has filed with th e S EC a Registration Statement on Form S - 4, containing a preliminary proxy statement/prospectus of Bull Horn and Coeptis and after the registration statement is declared effective, Bull Horn and Coeptis will mail a definitive proxy statement/prospectus relatin g t o the proposed Business Combination to their respective shareholders. 4 2022 Coeptis Therapeutics, Inc.
Information regarding the pers ons who may, under SEC rules, be deemed participants in the solicitation of proxies to Bull Horn's or Coeptis' shareholders in connec tio n with the Business Combination will be set forth in the proxy statement/prospectus included in the registration statement on Form S - 4 with respect to the Business Combination, which has been to be filed by Bull Horn with the SEC.
Investors and security holders may obtain more detailed information regarding the names and interests in the Bu sin ess Combination of Bull Horn's and Coeptis' respective directors and officers in Bull Horn's and Coeptis' filings with the SEC, i ncl uding Bull Horn's and Coeptis' respective Annual Reports on Form 10 - K for the fiscal year ended December 31, 2021.
INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF ANY OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. 3 2022 Coeptis Therapeutics, Inc.
No Offer or Solicitation: This Presentation is for informational purposes and does not constitute a "solicitation" pursuant to Section 14 of the Securities Exchange Act of 1934, as amended or the rules and regulations of the U.S. Securities and Exchange Commission ("SEC ") promulgated pursuant thereto. This Presentation does not constitute (i) a solicitation of a proxy, consent, or authorization wi th respect to any securities or in respect of the Business Combination or (ii) an offer to sell, a solicitation of an offer to buy, or a re com mendation to purchase any security of Bull Horn, Coeptis, or any of their respective affiliates nor shall there be any sale of securities, in vestment or other specific product in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qua lif ication under the securities laws of any such jurisdiction.
( "Bu ll Horn") and Coeptis Therapeutics, Inc. ("Coeptis"). The closing of the Business Combination will be subject to satisfaction o f t he closing condition set forth therein. In connection with the closing of the Business Combination, Bull Horn will re - domesticate as a Del aware corporation and will change its name. The continuing combined entity is hereinafter referred to as the "Company".